ECSP23036210A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents
Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetasInfo
- Publication number
- ECSP23036210A ECSP23036210A ECSENADI202336210A ECDI202336210A ECSP23036210A EC SP23036210 A ECSP23036210 A EC SP23036210A EC SENADI202336210 A ECSENADI202336210 A EC SENADI202336210A EC DI202336210 A ECDI202336210 A EC DI202336210A EC SP23036210 A ECSP23036210 A EC SP23036210A
- Authority
- EC
- Ecuador
- Prior art keywords
- cyclopentathiophen
- antagonists
- factor receptor
- platelet activation
- carboxamide derivatives
- Prior art date
Links
- ADEGUPDGFKUYII-UHFFFAOYSA-N 2H-cyclopenta[b]thiophene-2-carboxamide Chemical class S1C=2C(=CC1C(=O)N)C=CC=2 ADEGUPDGFKUYII-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000010118 platelet activation Effects 0.000 title 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract 1
- 108010003541 Platelet Activating Factor Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Ciclopentatiofen carboxamidas de la Fórmula (I.0), en donde R1, R2, R3, R4 y n son como se definen en la descripción y las reivindicaciones, y las sales de este aceptables desde el punto de vista farmacéutico pueden usarse en métodos para el tratamiento de enfermedades que pueden estar influenciadas por antagonizar la actividad mediada por el receptor del factor de activación de plaquetas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23036210A true ECSP23036210A (es) | 2023-06-30 |
Family
ID=73543025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202336210A ECSP23036210A (es) | 2020-11-16 | 2023-05-17 | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (es) |
| EP (1) | EP4244229A1 (es) |
| JP (1) | JP7465368B2 (es) |
| KR (1) | KR20230109692A (es) |
| CN (2) | CN116745300A (es) |
| AR (1) | AR124070A1 (es) |
| AU (1) | AU2021379248A1 (es) |
| CA (1) | CA3200710A1 (es) |
| CL (1) | CL2023001361A1 (es) |
| CO (1) | CO2023005894A2 (es) |
| CR (1) | CR20230211A (es) |
| DO (1) | DOP2023000090A (es) |
| EC (1) | ECSP23036210A (es) |
| IL (1) | IL302769A (es) |
| MX (1) | MX2023005678A (es) |
| TW (1) | TW202237620A (es) |
| WO (1) | WO2022101377A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| WO2008063667A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterotricyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko unknown
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en active Application Filing
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 CN CN202311341729.0A patent/CN117624188A/zh active Pending
- 2021-11-15 TW TW110142333A patent/TW202237620A/zh unknown
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230211A (es) | 2023-07-13 |
| US20230355638A1 (en) | 2023-11-09 |
| KR20230109692A (ko) | 2023-07-20 |
| JP2023521200A (ja) | 2023-05-23 |
| TW202237620A (zh) | 2022-10-01 |
| US20220160725A1 (en) | 2022-05-26 |
| AU2021379248A1 (en) | 2023-06-22 |
| CL2023001361A1 (es) | 2023-11-03 |
| IL302769A (en) | 2023-07-01 |
| CN117624188A (zh) | 2024-03-01 |
| CO2023005894A2 (es) | 2023-05-29 |
| AR124070A1 (es) | 2023-02-08 |
| JP7465368B2 (ja) | 2024-04-10 |
| WO2022101377A1 (en) | 2022-05-19 |
| MX2023005678A (es) | 2023-05-26 |
| DOP2023000090A (es) | 2023-06-15 |
| US11766443B2 (en) | 2023-09-26 |
| CA3200710A1 (en) | 2022-05-19 |
| CN116745300A (zh) | 2023-09-12 |
| EP4244229A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000038A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| UY28578A1 (es) | Derivados de amida | |
| NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
| AR070502A1 (es) | Derivado de sulfonilmalonamida, su uso farmaceutico y composiciones que los comprenden | |
| CR7880A (es) | Derivados sustituidos de pirrolo-pirazol como inhibidores de quinasa | |
| CR8928A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| AR023957A1 (es) | Pirazol carboxamidas utiles para el tratamiento de la obesidad y otros trastornos. | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| ECSP21036982A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
| UY28738A1 (es) | Deridos 1h-tieno(2,3-c)pirazol útiles como inhibidores de quinasa | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
| CO2021014155A2 (es) | Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 | |
| UY39517A (es) | Inhibidores de la btk | |
| AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
| ECSP23036210A (es) | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas | |
| CL2023002731A1 (es) | Análogos, sales, composiciones y métodos de uso de la psilocibina | |
| CL2023001574A1 (es) | Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicas | |
| CL2023001244A1 (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| PE20191549A1 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| DOP2022000203A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52 | |
| PE20181333A1 (es) | Derivados de indano y su uso en terapias | |
| AR050193A1 (es) | Derivados de benciloxi-oxopirrolidina como inhibidores de la mao; metodos para su preparacion y medicamentos para el tratamiento de enfermedades neurodegenerativas que los contienen. |